Predicting response to neoadjuvant chemotherapy in patients with cervical carcinoma: Can we do without any longer?

International Journal of Gynecological Cancer

Volumn 10, Issue 2, 2000, Pages 137-142

  De Jonge, E T M ^a,d   Lindeque, B G ^a   Burger, W ^b   Nesland, J M ^c   Holm, R ^c  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

Cervical cancer; Chemotherapy; Response

Indexed keywords

CATHEPSIN D; CISPLATIN; IFOSFAMIDE; MESNA; PROTEIN MDM2; PROTEIN P53;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CARCINOMA;

EID: 0034074738     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.00022.x     Document Type: Article

References (59)

1. Edelmann DZ, Anteby SO. Neoadjuvant chemotherapy for locally advanced cervical cancer - where does it stand?: a review. Obstet Gynecol Survey 1996;51:305-13.
2. Sardi JE, Giaroli A, Sananes C et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 1997;67:61-9.
3. Vermorken JB. Neoadjuvant chemotherapy (NACT) in cervical cancer: Still promising? Ann Oncol 1992;3:97-101.
4. Eifel PJ. Concurrent chemotherapy and radiation: a major advance for women with cervical cancer. J Clin Oncol 1999;17:1334-5.
5. Kim RY, Trotti A, Ching-Yung WU et al. Radiation alone in the treatment of cancer of the uterine cervix: analysis of pelvic failure and dose response relationship. Int J Radiat Oncol Biol Phys 1989;17:973-8.
6. Benedetti-Panici P, Landoni F, Greggi S et al. Randomized trial of neoadjuvant chemotherapy followed by radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: an Italian multicenter study. Int J Gynecol Cancer 1997;7 (Suppl.2):18 (Abstract).
7. Sardi JE, Sananes CE, Giaroli AA et al. Neoadjuvant chemotherapy in cervical carcinoma stage IIB. a randomized controlled trial. Int J Gynecol Cancer 1998;8:441-50.
8. Shueng PW, Hsu WL, Jen YM, Wu CJ, Liu HS. Neoadjuvant chemotherapy followed by radiotherapy should not be the standard approach for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 1998;40:889-96.
9. Kirsten F, Atkinson KH, Coppleson JVM et al. Combination chemotherapy followed by surgery or radiotherapy in patients with locally advanced cervical cancer. Br J Obstet Gynaecol 1987;94:583-8.
10. Symonds RP, Burnett RA, Habeshaw T, Kaye SB, Snee MP, Watson ER. The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of the cervix. Br J Cancer 1989;59:473-5.
11. Souhami L, Gil RA, Allan SE et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol 1991;9: 970-7.
12. Tattersal MHN, Lorvidhaya V, Vootiprux V et al. Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic irradiation in locally advanced cervical cancer. J Clin Oncol 1995;13:444-51.
13. Chang F, Syrjänen S, Syrjänen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995;13:1009-22.
14. Leborgne F, Leborgne JH, Doldan R et al. Induction chemotherapy and radiotherapy of advanced cancer of the cervix: a pilot study and phase III randomized trial. Int J Radiat Oncol Biol Phys 1997;37:343-50.
15. Kim SJ. Multimodal treatment for the locally advanced stage IB, IIA, IIB patients with cervical cancer. Int J Gynecol Obstet 1995;49:S49-S57.
16. Chauvergne J, Lhomme C, Rohart J et al. Neoadjuvant chemotherapy for stages IIB-III cervical cancers: long-term follow-up of pluricentric randomized study of 151 patients. Bull Cancer 1993;80:1069-79.
17. Sardi J, Sananes C, Giaroli A, Maya G, Di Paola G. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol 1990;38:486-93.
18. Benedetti Panici P, Scambia G, Baiocchi G et al. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer: prognostic factors for response and survival. Cancer 1991;67:372-9.
19. Kim DS, Moon H, Kim KT, Hwang YY, Cho SH, Kim SR. Two-year survival: pre-operative adjuvant chemotherapy in the treatment of cervical cancer stages Ib and II with bulky tumor. Gynecol Oncol 1989;33:225-30.
20. Deppe G, Malviya VK, Han I et al. A preliminary Report of combination chemotherapy with cisplatin and mitomycin-C followed by radical hysterectomy or radiation therapy in patients with locally advanced cervical cancer. Gynecol Oncol 1991;42:178-81.
21. de Jonge ETM, Falkson G, Burger W, Schoeman L, Lindeque BG. Neoadjuvant cisplatin plus ifosfamide in patients with stage IIB cervical cancer: a single center phase II study. Int J Gynecol Cancer 1997;7:158-62.
22. de Jonge ETM, Viljoen E, Lindeque BG, Amant F, Nesland JM, Holm R. The prognostic significance of p53, mdm2, c-erbB-2, cathepsin D, and thrombocytosis in stage IB cervical cancer treated by primary radical hysterectomy. Int J Gynecol Cancer 1999;9:198-205.
23. Hoskins WJ, Hoskins Lawton FG. Primary cytoreductive surgery for advanced-stage disease. In: Gershenson DM, McGuire WP, eds. Ovarian Cancer: Controversies in Management. New York: Churchill Livingstone, 1998: 65-84.
24. Bolis G, van Zainten-Przybysz I, Scarfone G et al. Determinants of response to a cisplatin-based regimen as neoadjuvant chemotherapy in stage IB-IIB invasive cervical cancer. Gynecol Oncol 1996;63:62-5.
25. Lai C, Hsueh S, Chang T et al. Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy. Gynecol Oncol 1997;64:456-62.
26. Hoffman B, Liebermann DA. Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive and negative modulators. Oncogene 1994;9:1807-12.
27. Deiss LP, Galinka H, Berissi H, Cohen O, Kimchi A. Cathepsin D protease mediates programmed cell death induced by interferon-gamma, FAS/APO-1 and TNF alfa. EMBO J 1996;15:3861-70.
28. Evan GI, Wyllie AH, Gilbert CS et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.
29. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
30. Itoh N, Yonehara S, Ishii A et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991;66:233-43.
31. Raff MC. Social controls on cell survival and cell death. Nature 1992;356:397-400.
32. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif 1991;24:203-14.
33. Dive C, Hickman JA. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br J Cancer 1991;64:192-6.
34. Clarke AR, Purdie CA, Harrison DJ et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-52.
35. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
36. Lowe SW, Earl Ruley H, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
37. Dittmer D, Pati S, Zambetti G et al. Gain of function mutations in p53. Nat Genet 1993;4:42-6.
38. Chin KV, Ueda K, Pastan I, Gottesman MM. Modulation of activity of the promotor of the human MDR1 gene by Ras and p53. Science 1992;255:459-62.
39. Nguyen KT, Liu B, Ueda K, Gottesman MM, Pastan I, Chin KV. Transactivation of the human multidrug resistance (MDR1) gene promotor by p53 mutants. Oncol Res 1994;6:71-7.
40. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
41. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
42. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
43. Ruley HR. p53 and response to chemotherapy and radiotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology Philadelphia: Lippincott-Raven Publishers, 1996: 37-56.
44. Garzetti GG, Ciavattini A, Provinciali M et al. Expression of p53 and apoptosis of tumour cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy. Anticancer Res 1996;16:3229-34.
45. Mueller H, Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 1996;16:3845-8.
46. Fan S, Smith ML, Rivet DJ et al. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifyllin. Cancer Res 1995;55:1649-54.
47. Koechli OR, Schaer GN, Seifert B et al. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 1994;344:1647-8.
48. Ueda M, Ueki K, Kumagai K et al. Apoptosis and tumor angiogenesis in cervical cancer after preoperative chemotherapy. Cancer Res 1998;58:2343-6.
49. Momand J, Zambetti GP, Olson DC, George D, Levine A. The mdm-2 oncogene product forms a complex with the p53 protein and inhibit p53-mediated transactivation. Cell 1992;69:1237-45.
50. 1 arrest and apoptotic functions of the p53 tumor suppressor protein. Mol Cell Biol 1996;16:2445-52.
51. Hynes NE. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1993;4:19-26.
52. Nakano T, Oka K, Ishikawa A, Morita S. Correlation of cervical carcinoma c-erbB-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997;79:513-20.
53. Kim YT, Kim JW, Kim DK, Song CH. Relationship between c-erbB-2 oncoprotein status and response to neoadjuvant chemotherapy in invasive cervical carcinoma. Int J Gynecol Cancer 1995;5:58 (Abstract).
54. Scambia G, Benedetti Panici P, Ferrandina G et al. Significance of cathepsin-D expression in uterine tumours. Eur J Cancer 1995;9:1449-54.
55. Hoffman RM. In vitro sensitivity assays in cancer: a review, analysis and prognosis. J Clin Lab Anal 1991;5:133-43.
56. Furukawa T, Kubota T, Watanabe M et al. High in vivo-in vitro correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 1992;51:489-98.
57. Furukawa T, Kubota T, Hoffman RM. Clinical applications of the histoculture drug response assay. Clin Cancer Res 1995;1:305-11.
58. Robbins KT, Connors KM, Storniolo AM, Hanchett C, Hoffman RM. Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Arch Otolaryngol Head Neck Surg 1994;120:288-92.
59. West CML, Davidson SE, Roberts SA, Hunter RD. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 1997;76:1184-90.